Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Press Release: Uppsala, December 15, 2023. Yesterday, the potency drug developer Dicot concluded the clinical part of the SAD, earlier than initially planned. Consequently, the company will be able to report these results already in the January-to-February transition. Results from the second and final part of the phase 1 trial are expected to be communicated in the second quarter of next year, as previously announced.
Dicot's phase 1 trial of the potency drug candidate LIB-01 is placebo-controlled and double-blinded, with the primary objective of investigating the safety profile in humans. The trial started in August of this year and consists of two parts: SAD (Single Ascending Dose) and MAD (Multiple Ascending Dose).
Yesterday the last participant in the SAD completed his final clinic visit, signifying that all participants have been dosed and undergone subsequent safety follow-up. Now, a period of data cleaning and analysis remains.
Dicot previously communicated that the trial results were expected to be presented during spring 2024. However, as the company now has successfully gathered all necessary data in the SAD earlier than originally planned, these results can be communicated already in the January-February month transition.
Simultaneously, the MAD is progressing as scheduled, with the first group of participants having received doses. Results from the MAD are expected to be communicated in the second quarter of 2024, as previously communicated.
"This is the first information we will receive about LIB-01 in humans, I'm very excited, and pleased that we have already managed to collect sufficient data to complete the SAD. The analysis and subsequent results represent a rapid and valuable increase in the understanding of our candidate and guides us in the development work ahead," commented Dicot's CEO, Elin Trampe.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 72 502 10 10
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 4,900 shareholders. For more information, please visit www.dicot.se.